AUM Biosciences together with A*STAR’s Singapore Immunology Network (SIgN) establish a new joint lab in Singapore, focussing on drug development and immune-monitoring of novel oncology drugs.
Cancer remains a major medical concern with one in every six deaths being related to the disease. Recent disruptive discoveries in cancer therapy have highlighted the critical role of targeting the host immune system in regulating cancer progression.
AUM Biosciences is an oncology-focused biotechnology company based in Singapore, it aims to boost the development of innovative, and affordable cancer medicines for oncology patients in Asia and across the world. In an announcement in August 2020, AUM Biosciences has teamed up with SIgN to construct a new joint lab for the development of novel therapeutics in oncology. This new lab will be established at Biopolis, Singapore’s biomedical research hub, where SIgN is currently located.
The joint lab will focus on the discovery of novel and proprietary immune biomarkers and understanding of drug mechanisms of action that can be translated to better clinical trial design and study endpoint analysis.
Professor Lam Kong Peng, Executive Director of SIgN, added, “We are excited to bring SIgN’s expertise in translational immunology to the joint lab to help accelerate the development of novel cancer therapies, and to support Singapore’s vibrant biotech scene through our collaboration.”
Dr. Harish Dave, CMO of AUM Biosciences, stated “AUM Biosciences is delighted to partner with SIgN in this exciting public – private collaboration. This represents the coming together of the best in translational research and industry to meet a common goal of delivering effective cancer therapeutics to patients.”
This collaboration will bring together the scientific expertise of SIgN in translational immunology, preclinical, and computational research and AUM Bioscience’s extensive capabilities in clinical trial design and management for improved targeted development programs for cancer therapies.
The timely partnership will synergize drug development and immune profiling efforts to advance the development of multiple small molecules through preclinical and clinical trials with the ultimate goal of bringing novel targeted oncology therapeutics to the market. [APBN]